Dr. Sanaz Memarzadeh is a board certified gynecologic oncologist. She specializes in the prevention, diagnosis and treatment of all gynecologic pre-invasive and invasive diseases. She has completed her residency at the UCLA medical Center. After the conclusion of her formal residency, she completed a three year fellowship training in gynecologic oncology at the UCLA Medical Center. This fellowship is designed to meet the subspecialty requirements of the Gynecologic Oncology Division of the American Board of Obstetrics and Gynecology and functions in concert with the Gynecologic Oncology Divisions at Cedars-Sinai and Kaiser Permanente. This fellowship has provided her with advanced surgical training for treatment of gynecologic cancers in addition to training in administration of chemotherapy and care for cancer patients.
Following her fellowship, Dr. Memarzadeh completed a Ph.D. in the department of Molecular Biology at UCLA. Dr. Memarzadeh performs basic science research at UCLA focusing on molecular pathways that lead to the development of gynecologic cancers. She has won multiple awards including the Reproductive Scientist Developmental Grant, the Ovarian Cancer Research Foundation Grant and a Gynecologic Cancer Foundation award. Dr. Memarzadeh has authored many published articles in respected journals and textbook chapters.
Dr. Memarzadeh currently maintains staff and operating room privileges at UCLA Westwood. She is accepting new patients seeking care in all aspects of gynecologic cancer or pre-cancerous diseases.
- PhD in Molecular Biology, UCLA, 2008
Dr. Sanaz Memarzadeh’s research in her laboratory, focuses on two poorly understood and under studied epithelial gynecologic malignancies endometrial and ovarian carcinoma. Even though both cancer subtypes pose a serious health risk to women little is known about what cells give rise to each tumor subtype, how these tumors initiate and strategies for targeted therapy. The goal of the laboratory is to identify ovarian and endometrial cancer initiating cells and targeting genetic pathways essential for their survival as part of the treatment for these gynecologic cancers. The G.O. Discovery team hypothesizes that the normal stem cells in the endometrium or ovary/fallopian tube could be the target cell for formation of endometrial or ovarian papillary serous carcinoma respectively. The normal epithelial stem of these gynecologic organs may also be precursors for ovarian and endometrial cancer stem cells. The lab aims to pinpoint the genetic changes that prompt normal gynecologic epithelial cells to convert into cancer cells and identify the chemical and biologic molecules that can be used to stop their growth. Such new therapies could be better tolerated with less side effects and better chances of eradicating these women’s cancers.
Lab website: www.godiscoverylab.com